Bremelanotide (PT-141) Nasal Spray Description 1-2 Bremelanotide is a melanocortin receptor (MCR) agonist
The Core Findings The combined data from these human trials revealed significant improvements in overall body composition, metabolic markers, and behavioral relationships with food: Key Statistics from the 12-Week Trials: 200%+ Average Increase in natural, circulating GLP-1 levels
Mahroum N, Alghory A, Kiyak Z, Alwani A, Seida R, Alrais M, et al
Pancreatitis associated with semaglutide may be under-reported because diabetic patients who qualify for GLP-1RA therapy often have other risk factors for acute pancreatitis, such as obesity, a longer duration of diabetes, and the use of other medications that independently increase pancreatitis risk